Therapy Detail

Therapy Name ALM201
Synonym
Therapy Description

ALM201 is a peptide therapy that is based on the human anti-angiogenic protein FKPB-L, which may decrease tumor cell migration and invasion and reduce formation of new vessels (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #383P).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
ALM201 ALM201 is a peptide therapy that is based on the human anti-angiogenic protein FKPB-L, which may decrease tumor cell migration and invasion and reduce formation of new vessels (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #383P).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor not applicable ALM201 Phase I Actionable In a Phase I trial, ALM201 demonstrated safety and acceptable pharmacokinetics in patients with advanced solid tumors, and 2 of 18 evaluable patients demonstrated stable disease for up to 6 cycles (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #383P). detail...
Clinical Trial Phase Therapies Title Recruitment Status